


April 28, 2003

Dr. Chad M. Wolf
ID Biomedical Corporation
19204 North Creek Parkway
Suite 100
Bothell, WA 98011

Dear Dr. Wolf,

This letter is to certify that the Washington State University Health Sciences Library (formerly the Veterinary Medical and Pharmacy Library) received a copy of the September 1993 issue of the journal *Vaccine* (volume 11, issue number 12) on October 14, 1993. Enclosed please find a copy of our date stamp found on the inside first page of the issue. If you have any further questions about the receipt of this issue at our library, please do not hesitate to contact me.

Sincerely,

Sarah K. McCord, MLIS
Reference Librarian

Vaccine is an international journal published 14 times a year, once every month and twice in March (issues 4 and 5) and August (issues 10 and 11), by Butterworth-Heinemann Ltd.

Publishing, Editorial, Production and Reprint Offices: Butterworth-Heinemann Ltd, Linacre House, Jordan Hill, Oxford OX2 8DP, UK. Telephone: +44 (0)865 310366. Facsimile: +44 (0)865 314412. Telex: 83111 BHPOXF G.

Publisher: Diane Cogan
Assistant Group Editor: Fionnula Russell
Editorial Controller: Louise Flanagan

Address for submissions: See Notes for Authors.

Subscription enquiries and orders in the UK and overseas should be sent to Turpin Distribution Services Ltd, Blackhorse Road, Letchworth, Herts SG6 1HN, UK. Telephone: +44 (0)462 672555. Facsimile: +44 (0)462 480947. Telex: 825372 TURPIN G. North American orders should be sent to Journals Fulfillment Department, Butterworth-Heinemann, 80 Montvale Avenue, Stoneham, MA 02180, USA. Telephone: +1 (617) 438 8464. Facsimile: +1 (617) 438 1479. Telex: 880052. Please state clearly the title of the journal and the year of subscription.

Annual subscription (14 issues): UK and Europe £380.00; rest of the world £410.00; private individuals certifying that copies are for their personal use and not for their libraries, and that copies are to be sent to their home address £75.00.

Single copies: UK and Europe £32.57; rest of the world £35.14. Prices include cost of postage and packing. Copies sent to subscribers in Australasia, Bangladesh, Canada, India, Japan, Pakistan, Sri Lanka and USA are airspeeded for faster delivery at no extra cost. Airmail prices are available on request. Payment must be made with order.

US mailing agents: Mercury Airfreight International Ltd, Inc., 2323 Randolph Avenue, Avenel, NJ 07001, USA. Second class postage paid at Rahway, NJ, USA.
US Postmaster: Send address corrections to *Vaccine*, c/o Mercury Airfreight International Ltd, Inc., 2323 Randolph Avenue, Avenel, NJ 07001, USA.

Back issues: For the current and 1992 volumes these are available from Turpin Distribution Services Ltd, at the address above. Complete volumes or single issues for earlier years are available from Wm Dawson, Cannon House, Folkestone CT19 5EE, UK. Telephone: +44 (0)303 850101. Facsimile: +44 (0)303 850440.

Advertising enquiries should be sent to Mark Butler, MTB Advertising, 11 Harts Gardens, Guildford GU2 6QA, UK. Telephone: +44 (0)483 578507. Facsimile: +44 (0)483 572678.

Microfilm: A microfilm version of *Vaccine* is available from University Microfilms Inc., 300 N. Zeeb Road, Ann Arbor, MI 48106-1348, USA.

Copyright: © Butterworth-Heinemann Ltd. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without either the prior written permission of Butterworth-Heinemann Ltd, or a licence permitting restricted photocopying in the United Kingdom issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, UK. For readers in the USA, this journal has been registered with the Copyright Clearance Center. Consent is given for copying articles for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition that the copier pay the per-copy fee of \$7.50 for copying beyond that permitted by Sections 107 or 108 of the US Copyright Law. The appropriate fee should be forwarded, quoting the code number at the end of this paragraph, to the Copyright Clearance Center, 21 Congress Street, Salem, MA 01970, USA. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works. Special written permission should be obtained from Butterworth-Heinemann for such copying. For readers in other territories, permission should be sought directly from Butterworth-Heinemann. *Vaccine* 0264-410X/93/\$7.50.

Reprints: Readers who require copies of papers published in this journal may either purchase reprints (minimum order 100) or obtain permission to copy from the publisher at the following address: Butterworth-Heinemann Ltd, Linacre House, Jordan Hill, Oxford OX2 8DP, UK.

No page charges are levied by this journal.

Registered Office: Butterworth-Heinemann Ltd, 88 Kingsway, London WC2B 6AB, UK.
A member of the Reed Elsevier group.

ISSN 0264-410X

This journal is printed on acid free, low chlorine bleach, wood free paper.

Typeset by P&R Typesetters Ltd, Salisbury, UK.
Printed by L.R. Printing Services Ltd, Burgess Hill, West Sussex, UK.

Vaccine

Volume 11 Number 12 September 1993
VACCDE 11(12) 1177-1272 ISSN 0264-410X

VETERINARY MEDICINE
LONDON

OCT 14 1993

WASHINGTON STATE UNIVERSITY

Contents

Review

- 1179 Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems
J. Holmgren, N. Lycke and C. Czerkinsky

Short Papers

- 1185 Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus
P. Vanlandschoot, G. Maertens, W.M. Jou and W. Fiers
- 1188 Haptoglobin polymorphism and the immune response after hepatitis B vaccination
H. Louagie, J. Delanghe, I. Desombere, M. De Buyzere, P. Hauser and G. Leroux-Roels

Papers

- 1191 Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors
B. Zheng, F.L. Graham, D.C. Johnson, T. Hanke, M.R. McDermott and L. Prevec
- 1199 GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3
P.O. Livingston, M.J. Calves, F. Helling, W.D. Zollinger, M.S. Blake and G.H. Lowell
- 1205 Induction of CD8⁺ cytotoxic T cells by immunization with killed influenza virus and effect of cholera toxin B subunit
I.N. Mbawuike and P.R. Wyde
- 1214 Transferrin-binding proteins isolated from *Neisseria meningitidis* elicit protective and bactericidal antibodies in laboratory animals
B. Danve, L. Lissolo, M. Mignon, P. Dumas, S. Colombani, A.B. Schryvers and M.-J. Quentin-Millet
- 1221 Expression and immunogenicity of the V3 loop from the envelope of human immunodeficiency virus type 1 in an attenuated *aroA* strain of *Salmonella typhimurium* upon genetic coupling to two *Escherichia coli* carrier proteins
A. Charbit, P. Martineau, J. Ronco, C. Leclerc, R. Lo-Man, V. Michel, D. O'Callaghan and M. Hofnung
- 1229 Hepatitis B vaccination and booster in predialysis patients: A 4-year analysis
C.S. Dukes, A.C. Street, J.F. Starling and J.D. Hamilton

Continued

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Dated: May 30, 2003Signature: Nora Durant

(Nora Durant)


Docket No.: 406462000102
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
George H. LOWELL

Application No.: 09/407,327

Filed: September 28, 1999

For: ORAL OR INTRANASAL VACCINES USING
HYDROPHOBIC COMPLEXES HAVING
PROTEOSOMES AND
LIPOPOLYSACCHARIDES

Group Art Unit: 1645

Examiner: R. Zeman

RECEIVED
JUN 05 2003
TECH CENTER 1600/2900DECLARATION OF GEORGE H. LOWELL, M.D.
UNDER 37 C.F.R. § 1.132Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I, GEORGE H. LOWELL, M.D., declare:

1. I am the sole inventor of the claimed subject matter in U.S. Patent Application No. 09/407,327 and am the last-listed co-author on the publication entitled, "GD3/proteosome vaccines induce consistent IgM antibodies against ganglioside GD3" in Vaccine, Volume 11, Issue 12, 1199-1204 (1993) and listing co-authors Philip O. Livingston, Michele J. Calves, Friedhelm Helling, Wendell D. Zollinger, and Milan S. Blake.
2. I am familiar with the contents of the patent application and the publication.
3. I designed the described vaccines for the uses described and the vaccines were prepared according to my specifications and instructions. In a conversation with Dr. Livingston, a clinician at Memorial Sloan-Kettering Cancer Center, I requested that he test the vaccines in a mouse model system. Dr. Livingston supervised Dr. Friedhelm Helling, a post doctoral candidate, and his technician, Michele Calves, in the administration of the vaccines, maintenance of the mice and performance of the serological assays for the experiments.

Application No.: 09/407,327**2**

4. Dr. Wendell Zollinger, a colleague of Dr. Lowell's at the Walter Reed Army Institute of Research, supplied the OMP (outer membrane proteins) of *Neisseria meningitides* 8047 and Dr. Milan S. Blake, of Rockefeller University, provided access to the OMP of *Neisseria gonorrhea*, the OMP from *Neisseria meningitides* 8765 and a monoclonal antibody used for these OMP.

6. Therefore, the other co-authors of the Vaccine article are not co-inventors of the subject matter claimed in the present application.

7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Executed in Montreal, Quebec, Canada on 30 May, 2003.

George H. Lowell M.D.
GEORGE H. LOWELL, M.D.